Article Text
Therapeutic intervention
Neurological immune-related adverse events of ipilimumab
Abstract
Ipilimumab enhances the T lymphocyte mediated immune response to both tumour cells and healthy tissue, improving survival in patients with metastatic melanoma but also leads to more immune-related adverse events (irAEs) than previously used treatments, such as dacarbazine. We present three patients with neurological irAEs from ipilimumab treatment: hypophysitis, meningitis and Guillain–Barré syndrome. Once an irAE occurs, ipilimumab should be stopped and corticosteroids started. Usually, ipilimumab-induced irAE symptoms improve within days to weeks, but can be life-threatening if unrecognised.
- NEUROONCOLOGY
- NEUROPHARMACOLOGY
Statistics from Altmetric.com
Linked Articles
- Editors' Choice
Read the full text or download the PDF:
Other content recommended for you
- Cardiotoxicity of immune checkpoint inhibitors
- Rare side effect of adjuvant ipilimumab after surgical resection of melanoma: Guillain-Barré syndrome
- Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort
- Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events
- Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy
- Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma
- Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
- Evolving impact of long-term survival results on metastatic melanoma treatment
- Challenge of immune-mediated adverse reactions in the emergency department
- Central nervous system complications associated with immune checkpoint inhibitors